Home | Coriolis Pharma

Coriolis Pharma Formulating innovation

For us innovation is progress achieved by collaboration. We generate innovation by combining technologies, knowledge and experience.

Formulating for us means to find the right solution.

About us

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.

As a family-owned and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our customers.

Formulation Development

“It is a medicine, not a molecule, that we are giving to the patient” Marc B. Brown, 2005.

Coriolis is the expert in developing liquid and lyophilized formulations for a large variety of different (bio)pharmaceutical molecules.

Find out how we can support your drug development...

Analytical Capabilities

A highly diverse analytical portfolio entirely performed in-house: This is Coriolis.

With the latest in technology and highly experienced scientists, we are a trendsetter in the field.

Get to know our services...

About us

Independent, reliable and always on the cutting edge of science. Coriolis is the leading service provider for formulation research and development of (bio)pharmaceutical drugs and vaccines.

Get to know us...

Latest news

2019/11/15

Coriolis scientific advisor to give Keynote Presentation at PEGS Europe

2019/11/13

Coriolis co-organizes workshop on protein stability

2019/11/11

Coriolis scientific advisor speaks at MIBio in Cambridge, UK

2019/11/05

Engage with Coriolis at Partnering Event in Hamburg

2019/11/05

Speed-Date Coriolis at the TUM Career Days

2019/10/18

Coriolis participates with three talks at AAPS PharmSci 360 event

2019/10/14

Coriolis CSO will talk at PDA workshop in Sweden

2019/10/07

Get to know us at the InPharma Symposium in Munich

2019/09/20

Coriolis will be present at PDA Europe event in Berlin

2019/09/18

Coriolis CTO present at conference in Munich

View all

Latest publications

Taking subvisible particle quantitation to the limit: Uncertainties and statistical challenges with ophthalmic products for intravitreal injection.

Gühlke M, Hecht J, Böhrer A, Hawe A, Nikels F, Garidel P, Menzen T.

Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life Cycle.

Mathaes R, Narhi L, Hawe A, Matter A, Bechtold-Peters K, Kenrick S, Kar S, Laskina O, Carpenter J, Cavicchi R, Koepf E, Lewis EN, De Silva R, Ripple D.

Factors Influencing Polysorbate's Sensitivity Against Enzymatic Hydrolysis and Oxidative Degradation.

Kranz W, Wuchner K, Corradini E, Berger M, Hawe A.

Intrinsic Differential Scanning Fluorimetry for Fast and Easy Identification of AAV Serotypes.

Rieser R, Penaud-Budloo M, Bouzelha M, Rossi A, Menzen T, Biel M, Büning H, Ayuso E, Winter G, Michalakis S.

Novel high-throughput assay for polysorbate quantification in biopharmaceutical products by using the fluorescent dye DiI.

Martos A, Berger M, Kranz W, Spanopoulou A, Menzen T, Friess W, Wuchner K, Hawe A.

What makes polysorbate functional? Impact of polysorbate 80 grade and quality on IgG stability during mechanical stress.

Grabarek AD, Bozic U, Rousel J, Menzen T, Kranz W, Wuchner K, Jiskoot W, Hawe A.

Stress Factors in Monoclonal Antibody Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy.

Das TK, Narhi LO, Sreedhara A, Menzen T, Grapentin C, Chou DK, Antochshuk V, Filipe V.

Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences

Crommelin D, Nastribattusta E, Hawe A, Hoogendoorn K and Jiskoot W.

Immunogenicity of therapeutic proteins.

Jiskoot W, Rispens T and Kijanka G.

Biophysical and biochemical characteristics of therapeutic proteins.

Jiskoot W and Crommelin DJA.

View all